Literature DB >> 2932193

Cardioprotection by the calcium antagonist PN 200-110 in the absence and presence of cardiodepression.

N S Cook, R P Hof.   

Abstract

The globally-ischaemic Langendorff rabbit heart model has been used to study the cardioprotective effects of the dihydropyridine PN 200-110 (PN) at two doses, one having no negative inotropic effect and a higher dose causing a 62 +/- 5% reduction in contractility. Following 45 min no-flow global ischaemia, recovery was monitored for a period of 90 min reperfusion. Hearts were paced at a constant rate throughout experiments. Contractile force and coronary flow were recorded continuously. Tracer microspheres were injected at regular intervals to assess regional flow distributions, drill biopsies were taken to determine tissue high energy phosphate content, and enzyme leakage in the coronary effluent measured during the first 15 min of reperfusion. Untreated hearts recovered 21 +/- 2% of their initial contractile force and flow to all heart regions was reduced. In particular, endocardial flow fell to 20% of its pre-ischaemic level, with the ratio of flow to the endocardium (endo)/epicardium (epi) decreasing from ca. 1.0 to 0.4. Hearts treated with 2 X 10(-8)M PN (included in the perfusate from 30 min before ischaemia until 30 min after ischaemia) recovered 49 +/- 2% of their initial, pretreatment contractile force, and following the ischaemia the endo/epi ratio was not significantly changed from the pre-ischaemic value. The lower PN dose (3 X 10(-10)M) afforded a lesser degree of protection, contractility recovering to 29 +/- 4% of the initial level, with an endo/epi ratio of 0.7 after 90 min reperfusion. 6 The two PN doses afforded a similar degree ofprotection against enzyme leakage which was in both cases significantly less than in untreated hearts. 7 Myocardial ATP and creatine phosphate content was markedly reduced by the ischaemic episode. Neither PN dose modified this depletion. 8 These results suggest that whilst cardiodepression may well offer protection against ischaemic damage, this is not the sole mechanism wherby PN (and possibly other calcium antagonists) can protect the heart. Preservation of blood flow to the inner layers of the left ventricular wall is likely to be one of the major factors underlying the enhanced recovery shown by PN.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932193      PMCID: PMC1916844          DOI: 10.1111/j.1476-5381.1985.tb09448.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Effects of diltiazem, a calcium antagonist, on regional myocardial function and mitochondria after brief coronary occlusion.

Authors:  T Nagao; M A Matlib; D Franklin; R W Millard; A Schwartz
Journal:  J Mol Cell Cardiol       Date:  1980-01       Impact factor: 5.000

2.  Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium.

Authors:  W G Nayler; R Ferrari; A Williams
Journal:  Am J Cardiol       Date:  1980-08       Impact factor: 2.778

3.  Protection of the myocardium against postischemic reperfusion damage. The combined effect of hypothermia and nifedipine.

Authors:  W G Nayler
Journal:  J Thorac Cardiovasc Surg       Date:  1982-12       Impact factor: 5.209

4.  The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs.

Authors:  K A Reimer; J E Lowe; M M Rasmussen; R B Jennings
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

5.  The effects of verapamil, quiescence, and cardioplegia on calcium exchange and mechanical function in ischemic rabbit myocardium.

Authors:  P D Bourdillon; P A Poole-Wilson
Journal:  Circ Res       Date:  1982-03       Impact factor: 17.367

6.  Trapping and intramyocardial distribution of microspheres with different diameters in cat and rabbit hearts in vitro.

Authors:  R P Hof; A Hof; R Salzmann; F Wyler
Journal:  Basic Res Cardiol       Date:  1981 Nov-Dec       Impact factor: 17.165

7.  Effects of nifedipine on myocardial perfusion and ischemic injury in dogs.

Authors:  P D Henry; R Shuchleib; L J Borda; R Roberts; J R Williamson; B E Sobel
Journal:  Circ Res       Date:  1978-09       Impact factor: 17.367

8.  Microbiopsy metabolite and paired flow analysis: a new rapid procedure for homogenisation, extraction and analysis of high energy phosphates and other intermediates without any errors from tissue loss.

Authors:  D J Hearse
Journal:  Cardiovasc Res       Date:  1984-06       Impact factor: 10.787

9.  Effects of Ca2+ antagonism on energy metabolism: Ca2+ and heart function after ischemia.

Authors:  J A Watts; C D Koch; K F LaNoue
Journal:  Am J Physiol       Date:  1980-06

10.  Variable effect of nifedipine on myocardial blood flow at three grades of coronary occlusion in the dog.

Authors:  W S Weintraub; S Hattori; J Agarwal; M M Bodenheimer; V S Banka; R H Helfant
Journal:  Circ Res       Date:  1981-06       Impact factor: 17.367

View more
  3 in total

1.  Stereoisomers of BAY K 8644 show opposite activities in the normal and ischaemic rat heart. A comparison with nifedipine.

Authors:  F T van Amsterdam; N C Punt; M Haas; M S van Amsterdam-Magnoni; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

Review 2.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

3.  Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.

Authors:  F L Tse; J M Jaffe
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.